Veronique Lheritier

Pierre-la-treiche, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: February 01, 2026

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Journal: Blood
Published: January 20, 2026

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Journal: Blood
Published: January 20, 2026

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC.

Journal: Bone marrow transplantation
Published: December 11, 2025

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL.

LEF1 intragenic deletion induces a dominant-negative isoform and unveils a Wnt/β-catenin vulnerability in T-ALL.

Journal: Blood
Published: June 02, 2025

Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.

Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.

Journal: Blood
Published: April 15, 2025

Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.

Age-adapted chemotherapy and MRD-oriented transplant for Ph-negative acute lymphoblastic leukemia: the GRAALL-2014 trial.

Journal: Blood
Published: April 15, 2025

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry.

Journal: Blood advances
Published: June 13, 2024

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.

NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients.

Journal: Blood
Published: January 10, 2024

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.

Journal: Blood
Published: December 15, 2023

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2023
Showing 1-12 of 37

Last Updated: 09/26/2026